See more : Brookfield Renewable Partners L.P. (BEP-PA) Income Statement Analysis – Financial Results
Complete financial analysis of Allogene Therapeutics, Inc. (ALLO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Allogene Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- China Infrastructure & Logistics Group Ltd. (1719.HK) Income Statement Analysis – Financial Results
- Flying Spark Ltd. (FLYS.TA) Income Statement Analysis – Financial Results
- Global Unichip Corp. (3443.TW) Income Statement Analysis – Financial Results
- Mid Penn Bancorp, Inc. (MPB) Income Statement Analysis – Financial Results
- TYK Corporation (5363.T) Income Statement Analysis – Financial Results
Allogene Therapeutics, Inc. (ALLO)
About Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 95.00K | 243.00K | 38.49M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 242.91M | 16.73M | 13.07M | 11.54M | 5.03M | 1.50M | 0.00 |
| Gross Profit | -242.82M | -16.49M | 25.42M | -11.54M | -5.03M | -1.50M | 0.00 |
| Gross Profit Ratio | -255,598.95% | -6,783.95% | 66.06% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 242.91M | 256.39M | 220.18M | 192.99M | 144.54M | 151.86M | 0.00 |
| General & Administrative | 71.67M | 79.31M | 74.11M | 65.26M | 57.47M | 40.98M | 24.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -22.00K |
| SG&A | 71.67M | 79.31M | 74.11M | 65.26M | 57.47M | 40.98M | 2.00K |
| Other Expenses | 13.25M | -1.75M | -2.93M | -1.14M | -268.00K | -21.21M | 0.00 |
| Operating Expenses | 327.83M | 335.69M | 294.28M | 258.24M | 202.01M | 192.84M | 2.00K |
| Cost & Expenses | 327.83M | 335.69M | 294.28M | 258.24M | 202.01M | 192.84M | 2.00K |
| Interest Income | 18.31M | 4.57M | 1.71M | 9.16M | 17.35M | 5.79M | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.36M | 0.00 |
| Depreciation & Amortization | 14.20M | 14.30M | 10.45M | 11.54M | 5.03M | 1.50M | 24.00K |
| EBITDA | -300.29M | -321.24M | -169.74M | -250.81M | -179.90M | -206.76M | 22.00K |
| EBITDA Ratio | -316,097.89% | -138,044.86% | -664.58% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -327.74M | -335.45M | -255.79M | -258.24M | -202.01M | -192.84M | -2.00K |
| Operating Income Ratio | -344,986.32% | -138,044.86% | -664.58% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 472.00K | -4.88M | -1.86M | 8.02M | 17.08M | -18.78M | -22.00K |
| Income Before Tax | -327.27M | -332.63M | -257.01M | -250.22M | -184.93M | -211.62M | -2.00K |
| Income Before Tax Ratio | -344,489.47% | -136,885.60% | -667.74% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -2.82M | -12.17M | -16.75M | -331.00K | -117.00K | -24.00K |
| Net Income | -327.27M | -329.82M | -244.84M | -233.47M | -184.59M | -211.51M | -2.00K |
| Net Income Ratio | -344,489.47% | -135,726.34% | -636.12% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.09 | -2.30 | -1.80 | -1.94 | -1.83 | -7.31 | 0.00 |
| EPS Diluted | -2.09 | -2.30 | -1.80 | -1.94 | -1.83 | -7.31 | 0.00 |
| Weighted Avg Shares Out | 156.93M | 143.15M | 135.82M | 120.37M | 101.06M | 28.95M | 117.93M |
| Weighted Avg Shares Out (Dil) | 156.93M | 143.15M | 135.82M | 120.37M | 101.06M | 28.95M | 117.93M |
Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock?
Allogene Therapeutics (ALLO) Upgraded to Buy: Here's Why
Allogene Therapeutics Announces Participation in December Investor Conferences
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence
Allogene's Q3 Loss Narrower Than Expected, Sales Nil
Allogene Therapeutics, Inc. (ALLO) Q3 2024 Earnings Call Transcript
Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update
Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS
Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting
Will Allogene Therapeutics (ALLO) Report Negative Earnings Next Week? What You Should Know
Source: https://incomestatements.info
Category: Stock Reports